The following is a summary of the Cardlytics, Inc. (CDLX) Q1 2024 Earnings Call Transcript:

Financial Performance:

• Cardlytics raised $50 million in cash and reported positive adjusted EBITDA for full-year 2023 and Q1 2024.

• Struck a 12% growth in Q1 billings over the first quarter of 2023, indicating advertiser interest.

• Adjusted contribution, reflecting business performance, saw a 27% growth over the first quarter of 2023.

• Closed Q1 with adjusted EBITDA of $0.2 million, a company first for the first quarter.

• Ended Q1 with a total of $97.8 million in cash and cash equivalents.

Business Progress:

• The company has put capital concerns to bed and has entered into a new phase focusing on long-term growth prospects.

• Steady technological improvement, product development and team enhancement have been carried out for anticipated growth.

• Currently constructing a dynamic marketplace for meeting campaign optimizations, timely reporting, and dynamic pricing.

• Looking to invest more in the technology and sales team to boost engagement and yield superior results.

• Involved in the development of Rippl, expected to become one of the most extensive retail media networks in the country.

• For 2024, the company aims to sustain higher growth rates.

• Initiating further engagement among consumers and revising revenue-sharing agreements with banking partners.

• Investments planned in technological up-gradation and product innovation for better client servicing.

• The target is to provide automated insights to 10% of consumers through the self-serve platform by the end of Q2 2024, with ambitions to roll out the ability to book budgets without team intervention in the long-term.

• Focus also on the development of Bridg and Rippl products aimed at increasing the number of profiles and widening the customer targeting landscape, with a mission to reach 100 million profiles by the end of the year.

More details: Cardlytics IR

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.